In part 1, Locke explained how CAR T-cell therapy works and the differences between autologous and allogeneic CAR T-cell therapy.

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD).